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Introduction
Retinoblastoma is a genetically determined tumor which repre-
sents the most common intraocular malignancy of infancy and 
early childhood.1 It represents the prototypic model for inher-
ited cancers with the pivotal genetic event being the inactivation 
of both copies of RB1 gene at the chromosomal locus 13q14.2 
This determines the inactivation or loss of the retinoblastoma 
protein (pRb) which, in normal conditions, targets E2F1 tran-
scription factor blocking entry into the S phase of cell cycle.3 
Retinoblastoma equally affects both genders and all races and 
is responsible for 1% of cancer deaths of children and 5% of 
blindness. Most children are diagnosed with retinoblastoma in 
the first or second year of life, although later presentation can 
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occur, and very rare cases have even been reported in adults.4 
The cells of origin are postulated to be retinal stem cells or 
retinal progenitor cells.5 The untreatment of retinoblastoma is 
always fatal and the patients die of intracranial extension and 
disseminated disease within two years. The first goal of treat-
ment is survival, followed by globe salvage, then preservation of 
vision. In the last years repeated cycles of chemotherapy with 
carboplatin, vincristine and etoposide combined with cryo-
therapy and laser photocoagulation have improved the ocular 
salvage rate for children with bilateral retinoblastoma,6 and 
treatment in the early stages of disease holds a good progno-
sis for survival and salvage of visual function. In late stages, 
however, the prognosis for ocular function and even survival 
is jeopardized and children often experience recurrence after 
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synergistic apoptotic effects in human retinoblastoma Y79 cells. 
We also describe the possible molecular mechanism of this syn-
ergistic effect.
Results
Okadaic acid and parthenolide combination sinergistically 
induce cytotoxicity in Y79 cells. We first examined the survival 
rate of human retinoblastoma Y79 cells after treatment with 
OKA and PN alone. Monolayer cells were treated for various 
times (3–48 h) with various doses of OKA (5–50 nM) or PN (50 
nM–2 μM) and viability was studied by MTT assay. As shown 
in Figure 1A, treatment with either OKA or PN determined 
a time- and dose-dependent loss of cell viability. At 48 h after 
treatment, 5–30 nM OKA determined only little effects (5–20% 
loss of cell viability); the effects significantly increased with 40 
nM (35% loss of cell viability) and reached their maximum with 
50 nM (70% loss of cell viability). Figure 1A also shows that 
similar loss of cell viability was induced by treatment with PN 
alone within the range of concentrations of 50–500 nM, 1 μM, 
and 2 μM. To evaluate whether OKA/PN combination syner-
gistically induces cytotoxic effects, a dose- and time-dependent 
effect analysis according to Chou and Talalay method was per-
formed.22 Three different suboptimal concentrations of OKA 
(10, 20, and 30 nM) and two suboptimal concentrations of 
PN (250 and 500 nM) were chosen and assessed in combina-
tion. Figure 1B shows the results obtained when Y79 cells were 
treated for various times (3–12 h) with OKA/PN combination 
at concentrations which changed in a fixed ratio. As Figure 1B 
shows, the decrease in cell survival was much greater with 
the combined treatment than with single-drug treatments. In 
Figure 1C analysis of the combination index (CI) with respect to 
the proportion of dead cells (fraction affected, Fa) showed values 
of CI considerably lesser than 1.0, indicating strong synergistic 
interactions between the two compounds. To useful continue 
our study, we established to employ, when not otherwise speci-
fied, the combined concentrations of 20 nM OKA and 500 nM 
PN (since then indicated as OKA/PN), for 6 h of treatment, a 
condition that, as shown in Figure 1B, resulted in not more than 
50% loss of cell viability.
Treatment with OKA/PN induces apoptotic morphology. 
To elucidate the mechanism by which OKA/PN induced loss of 
cell viability in Y79 cells, we performed morphological analysis. 
In Figure 2A phase contrast (PC) microscopy shows that 6 h of 
OKA/PN treatment reduced cell number, also inducing dramatic 
modifications in cell shape, with rounding and loss of cell-cell 
contact. The effect seemed to be apoptotic as suggested by mem-
brane blebbing, formation of apoptotic bodies and a tendency of 
cells to coat in the medium. Figure 2A shows that single-drug 
treatment did not change the number and the cell morphology. 
As chromatin condensation and nuclear fragmentation remain 
the hallmarks of apoptotic cells, apoptosis was assessed by nucleic 
acid staining. In Figure 2B Hoechst 33258 (H) staining shows 
that OKA/PN treatment induced typical apoptotic nuclei exhib-
iting highly fluorescent condensed chromatin, with bright blue 
spots, whereas control cells and cells treated with OKA or PN 
treatment. In addition, as ototoxicity is a possible side effect 
of carboplatin,7 the evaluation of hearing loss in patients who 
frequently have impaired vision is very important. Children 
with the inherited form have a high risk of developing other 
cancers later in life4 and very long-term follow-up of retinoblas-
toma patients revealed an emerging excess risk of mortality in 
hereditary retinoblastoma survivors. After 50 years of follow-
up, hereditary retinoblastoma survivors, most of whom were 
treated with radiotherapy, had a 25.5% cumulative risk of dying 
from a subsequent malignant neoplasm compared with a 1.0% 
cumulative risk for nonhereditary retinoblastoma survivors, 
most of whom were treated surgically.8 The high mortality risks 
persisted for cancers of the bone, connective tissue, brain and 
other parts of the nervous system, and for melanoma.
In the past 15 years our laboratory was actively engaged in 
studying the cytotoxic effect of drugs in human retinoblastoma 
cells and their molecular mechanism of action. Our studies, per-
formed in human Y79 retinoblastoma cells, have demonstrated 
that in these cells the lack of functional pRb is accompanied by 
upregulation of p53 and this makes Y79 cells prone to apopto-
sis.9 We have also shown that a number of drugs act as apoptotic 
inducers in Y79 cells through either extrinsic or intrinsic path-
ways, via p53-independent or -dependent mechanisms,10,11 and 
with some drugs inducing significant synergistic effects when 
employed in combination.12
Recently, our attention has been paid to the use of natural 
compounds that do not have cytotoxic effects on normal cells 
and exert potent cytotoxic effects on cancer cells. We have dem-
onstrated that paclitaxel (PTX), a complex diterpene isolated 
from Taxus Brevifolia, whose target is the mitotic tubulin/
microtubule system, is a potent inducer of apoptosis in human 
Y79 retinoblastoma cells;13 in addition, when subtoxic doses of 
PTX and β-lapachone (LPC)—a natural naphthoquinone com-
pound extracted from the bark of the lapacho tree Tabebuia avel-
lanedae—were combined, they potently synergized in inducing 
apoptosis.14
Here, we investigated the effects of parthenolide (PN), 
a sesquiterpene lactones derived from the leaves of feverfew 
(Tanacetum parthenium), and of okadaic acid (OKA), a lipophilic 
derivative of a C38 fatty acid produced by several marine dino-
flagellates and isolated from the sponges Halichondria okadai and 
Halichondria melanodocia.
PN has attracted much attention because of its anti-inflamma-
tory and anti-cancer activities.15-18 PN contains an α-methylene-
γ-lactone ring and an epoxide moiety which are able to interact 
with nucleophilic sites of biologically important molecules thus 
modulating multiple targets and contributing to its various in 
vitro and in vivo effects.19
OKA acts by inhibiting serine/threonine protein phosphatases 
(PP1 and specially PP2A)20 and this results in the hyperphos-
phorylation of many cell proteins with the disregulation of a vari-
ety of cellular processes. Apoptosis has been widely reported as a 
relevant mechanism of OKA-mediated toxicity; however, molec-
ular pathways in OKA-driven apoptosis still remain unclear.21
Here, we demonstrate for the first time that subtoxic doses 
of OKA/PN combinations are particularly effective in inducing 
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caspase 8 was evidenced as indicated by the increase in the active 
fragment level, with a small reduction in that of procaspase form. 
Treatment with OKA or PN alone also activated initiator caspase 
8 but at a lesser degree than OKA/PN combination. Moreover, 
OKA/PN treatment activated the executioner caspase 3, caused 
the cleavage of Lamin B and reduced PARP level (Fig. 3E). At 
12 h after OKA/PN treatment the levels of the analyzed proteins 
resulted similar to those described at 6 h after treatment (not 
shown).
OKA/PN treatment potently increases ROS levels and low-
ers GSH content. Recent studies have demonstrated that par-
thenolide induces apoptosis via multiple mechanisms including 
generation of reactive oxygen species (ROS).23 We were inter-
ested in evaluating whether apoptosis induced in Y79 cells by 
OKA/PN treatment even involved oxidative stress. To evaluate 
such an involvement, we measured intracellular free radical levels 
at various time-intervals (3–12 h) after drugs treatment, using 
the cell permeant dye H2-DCFDA. In Figure 4A measurements 
of H2-DCFDA fluorescence show that OKA/PN generated an 
increase in intracellular ROS which was already evident at 3 h 
after treatment, exhibited its maximum level at 6 h and pro-
gressively lowered at 9 and 12 h. Figure 4B shows the shift of 
fluorescence intensity observed at 6 h after OKA/PN treatment 
indicating the potent increase in ROS levels. As Figure 4B shows, 
neither OKA nor PN alone increased ROS levels. To determine 
whether ROS increase was accompanied by glutathione (GSH) 
consumption, we measured cellular GSH content using a colori-
metric assay kit. The Figure 4C shows that OKA/PN treatment 
strongly reduced GSH content, with the concomitant increase 
in ROS level described in Figure 4A. Indeed, GSH content 
reached its lower level after 6 h treatment with OKA/PN and 
progressively recovered thereafter. After single-drug treatment 
only a small GSH decrease was measured. To verify whether 
GSH lowering could be responsible for the loss of cell viability 
alone appeared normal, with nuclei staining weakly and homoge-
neously distributed. In Figure 2C the fluorescent dye technique 
by using A/E staining shows that OKA/PN treatment resulted 
in nuclear fragmentation with the coexistence of both, cells 
with nuclei presenting green bright spots (live-apoptotic cells), 
and cells with nuclei presenting red bright spots (dead-apoptotic 
cells). Control cells and cells treated with OKA or PN alone 
appeared normal, with uniform green nuclei.
Cytofluorimetric and western blot analyses confirm that 
OKA/PN treatment induces apoptosis. We performed cyto-
fluorimetric analysis in the presence of propidium iodide, in 
order to quantify the percentage of cells in sub-G
0
-G
1
 phase. 
Bar histograms in Figure 3A show that at 3, 6, 12, and 24 h 
after treatment OKA/PN significantly induced cell accumula-
tion in sub-G
0
/G
1
 phase. A small effect was already evident at 
3 h after treatment (~8%), peaked at 6 h (~50%), was maxi-
mal at 12 h (62%), and did not change significantly thereafter. 
Neither OKA, nor PN alone induced sub-G
0
-G
1
 phase accumu-
lation. In Figure 3B DNA content analysis describes as, at 6 h 
after OKA/PN treatment, cell cycle profile resulted in 50.3% 
accumulation of the cells in the sub-G
0
-G
1
 phase with concomi-
tant loss from G
0
-G
1
 and G
2
-M phases. To further confirm that 
the sub G
0
/G
1
 peak was due to apoptosis and not necrosis, we 
performed Annexin V assay by flow cytometry. In Figure 3C 
cytofluorimetric analysis evidences that the cells accumulated in 
the sub-G
0
-G
1
 phase after OKA/PN treatments also contained 
a significant percentage of cells in early apoptosis. In Figure 
3D the analysis describes the Annexin V/PI pattern at 6 h after 
OKA/PN treatment.
We also investigated whether during the 3–12 h of OKA/PN 
treatment initiator and executioner caspases resulted activated. 
No activations were seen at 3 h after treatment either with sin-
gle-drug or with OKA/PN treatment (not shown). At 6 h after 
OKA/PN treatment (Fig. 3E), a marked activation of initiator 
Figure 1. synergistic interaction of OKa and PN in human retinoblastoma Y79 cells. The figure describes the time-and dose-dependent effects of OKa 
and PN treatment (A) and the effects of their combination (B) analyzed by MTT assay. Data are the mean ± sD of three independent experiments, each 
performed in triplicate, and expressed as percentage of the control. Data were considered significant at *P < 0.05 and highly significant at #P < 0.01 as 
compared with the control group. (C) Values of combination index (CI) were calculated in relation to the fraction affected (Fa). Values of CI less than 1.0 
indicate synergistic interactions between the two drugs.
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In Figure S1 western blot analysis shows that PTEN levels mark-
edly increased, after OKA/PN treatment, long before than p53, 
with PTEN increasing being accompanied by potent lowering in 
p-Akt and pS166-Mdm2 levels.
Silencing PTEN gene subverts the levels of the molecular 
players which control apoptosis. To establish whether PTEN 
may be the key player in the activation of the apoptotic path-
way, we have depleted PTEN gene by small-interfering-RNA 
(siRNA).
First, we checked the effects of PTEN-targeting siRNA on the 
expression of endogenous PTEN in Y79 cells. Cells transfected 
with scrambled siRNA (Scr-siRNA) were employed as control. 
In Figure 6A western blot analysis shows that, after 24–72 h of 
PTEN-siRNA transfection, PTEN levels potently lowered. The 
effects were observed at 24 h after transfection and peaked at 
48 h. Thereafter, PTEN levels went up markedly, so that at 72 h 
after transfection we only observed a small decrease in its level. 
This suggested that, at that time, the temporary transcriptional 
silencing was in rapid recovery. Overall, the results suggested that 
the optimal silencing efficiency was reached at 48 h after trans-
fection. The knockdown of PTEN protein was specific, as no 
PTEN protein reduction was observed in cells transfected with 
Scr-siRNA. Therefore, either Scr-siRNA or PTEN-siRNA cells 
transfected, at 48 h after transfection, and untransfected cells 
were treated with the drugs for 6 h. Figure 6B shows that in 
Scr-siRNA transfected cells, OKA/PN treatment determined the 
same effects induced in untransfected cells (i.e., a potent increase 
in PTEN levels) instead, in PTEN-siRNA transfected cells, 
OKA/PN treatment failed to raise the low levels of PTEN deter-
mined by its silencing. Figure 6B also shows that, similarly to the 
effect determined on PTEN levels, OKA/PN failed to raise the 
low levels of p53 determined by PTEN silencing. With regard to 
the effects of OKA/PN on the levels of p-Akt and pS166-Mdm2, 
induced by OKA/PN treatment, Y79 cells were pre-treated (4 h) 
with a non-toxic dose (100 μM) of the glutathione depleting 
agent l-butathionine-[S,R]-sulfoximine (BSO), a compound 
that, by inhibiting GSH synthesis, reduces cellular GSH level. 
Thereafter, the cells were treated for 3 h with the drugs and cell 
viability by MTT assay was measured. As shown in Figure 4D, 
in comparison with unpretreated cells, in BSO-pre-treated cells, 
3 h of OKA/PN treatment resulted in a potent loss (−35%) of 
cell viability, whereas single-drug treatments did not determine 
reduction of cell viability. This suggests that the GSH decrease 
promoted by BSO anticipated OKA/PN time-dependent effects 
and described in Figure 1B. Overall, the results suggested that 
in Y79 cells GSH could be a critical factor in the control of cell 
survival/death.
OKA/PN treatment induces phospho-Akt and phospho-
Mdm2 lowering, p53 increase, stabilization and activation, 
with PTEN being the key player. Here we evaluated whether 
PTEN (phosphatase and tensin homolog deleted on chromo-
some 10), a tumor suppressor recently involved in the regulation 
of cell fate, in particular senescence and apoptosis,24 is involved 
in the effects induced by OKA/PN treatment. We also analyzed 
the status of the serine-threonine kinase Akt, as it is known that 
PTEN specifically dephosphorylate phosphatidylinositol-3,4,5-
trisphosphate (PIP3), thus antagonizing phosphatidylinositol 
3-kinase (PI3K) activity and negatively regulating Akt, its down-
stream target. In Figure 5A western blot analysis shows that Y79 
cells expressed significant basal levels of PTEN which markedly 
increased at 6 h after OKA/PN treatment. Figure 5A also shows 
that OKA/PN treatment did not modify Akt levels, whereas it 
markedly decreased the levels of p-Akt, its active form. No effects 
were determined by treatment with single-drugs.
Knowing that PI3K–Akt signaling can control p53 functions 
by regulating Mdm2 localization,25 we examined the effects 
of OKA/PN treatment on the levels of both p53 and pS166-
Mdm2. As Figure 5A shows at 6 h after OKA/PN treatment 
p53 potently increased and pS166-Mdm2 potently decreased, 
while Mdm2 did not change. Little effects were seen with single-
drug treatments. We then decided to verify both the status of 
p53 and its cell localization. In Figure 5B western blot analyses 
of phosphorylated (p) and acetylated (ac) p53 forms show that 
6 h of OKA/PN treatment markedly increased the basal levels 
of p-Ser46-p53 and ac-Lys-373/382-p53. The results suggested 
that these effects could be responsible for p53 stabilization and 
its trapping in the nucleus. The figure also shows that OKA/PN 
treatment potently increased the levels of both p21WAF1 and bax, 
thus suggesting that p53 is transcriptionally active. Also single-
drug treatment increased the levels of these proteins, but these 
effects were much lesser strong than with combined treatment.
In Figure 5C immunofluorescence analysis of p53 intracel-
lular localization shows that 6 h of OKA/PN treatment induced 
a potent increase in p53 levels with its massive nuclear accumula-
tion, as highlighted by merged image. Only small effects on p53 
were observed with single-drug treatment.
Aimed at identifying the molecular player responsible for the 
effects activated by OKA/PN treatment, we analyzed the effects 
induced by the drugs at early times of treatment (30–120 min). 
Figure 2. apoptotic effects induced by OKa/PN combination in human 
retinoblastoma Y79 cells. The figure describes the effects OKa and 
PN treatment on cell morphology analyzed by (A) phase contrast (PC) 
microscopy, (B) fluorescence microscopy by hoechst 33258 (h) staining, 
(C) fluorescence microscopy by acridine orange/ethidium bromide (a/e) 
staining. (Original magnification 400×). Images are representative of at 
least four independent experiments.
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in developing countries, where treatment is limited and long-
term survival rates are low. In addition, existing therapies for 
retinoblastoma (i.e., chemotherapy and focal therapies) result in 
unfavorable outcomes at both the systemic and local levels.27,28 
Vincristine, etoposide, and carboplatin—the agents commonly 
used systemically in the treatment of retinoblastoma—determine 
side effects (abdominal pain, nausea, vomiting, and myelosup-
pression) which cause significant morbidity to pediatric patients 
and significantly limit dosing.29 Thus, the identification of both 
new drugs and new molecular targets is necessary to facilitate the 
development of novel therapeutics.
The search for drugs that are non-cytotoxic to normal cells 
and can effectively target cancer cells has led to the discov-
ery of the potent anticancer activity of some natural products 
which are chemopreventive or therapeutic against cancers.30 One 
major goal of anticancer drug discovery is to develop innovative 
therapies that exhibit a real improvement in effectiveness and/
or tolerability. To found natural drug combinations which can 
the results show that, in comparison with untransfected and Scr-
siRNA transfected cells—where OKA/PN treatment potently 
lowered their levels—in PTEN-siRNA transfected cells OKA/
PN treatment was unable to reduce p-Akt and pS166-Mdm2 lev-
els. We also studied the effect of OKA/PN treatment on GSH 
content and on cell viability. As Figure 6C shows, in PTEN-
siRNA cells at 6 h after OKA/PN treatment were observed only 
modest effects on either GSH content or cell viability. Instead, 
at 12 h GSH levels decreased by about 25% and cell viability 
decreased by about 38%. Overall, the findings suggest that 
PTEN can be the key player that orchestrates the molecular 
events involved in the activation of the apoptotic pathway.
Discussion
Retinoblastoma is considered a curable cancer in the developed 
world, yet it can cause significant morbidity and, rarely, mor-
tality.26 However, 80% of all the pediatric malignancies occurs 
Figure 3. OKa/PN treatment induces apoptosis and activation of caspases in human retinoblastoma Y79 cells. (A) Graph summarizing percentages of 
cells in sub-G0-G1 phase, evaluated by flow cytometric analysis of propidium iodide DNa staining. Data are the mean ± sD of three independent ex-
periments, each performed in triplicate. Data were considered significant at *P < 0.05 and highly significant at #P < 0.01 as compared with the control 
group. (B) Cell cycle profile at 6 h after OKa, PN, and OKa/PN treatment. (C) Graph summarizing percentages of early apoptotic cells (annexin V+/PI−) 
measured by flow cytometric analysis of annexin V labeling. Data are the mean ± sD of three independent experiments, each performed in triplicate. 
Data were considered significant at #P < 0.01 as compared with the control group. (D) Typical contour plots at 6 h after OKa, PN and OKa/PN treat-
ment. (E) Western blot analysis of apoptotic markers. actin was used as the loading control. Images are representative of at least four independent 
experiments.
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kill cancer cells by synergistically acting at sub-
toxic doses, may be a good goal. Recently, we 
have demonstrated that, in Y79 cells, PTX/LPC 
combination at subtoxic doses potently induces 
apoptosis accompanied by potent lowering in 
proteins inhibitor of apoptosis and by activation 
of Bid and caspases 3 and 6 with lamin B and 
PARP breakdown.14 We have also shown that Y79 
cells contain constitutively activated Akt which 
counteracts apoptotic signals by forming a cyto-
solic complex with p53 and pS166-Mdm2. It is 
known that pS166-Mdm2 can enter the nucleus 
where it can induce p53 export, thus trapping it 
in the cytosolic complex which drives its degrada-
tion by ubiquitin–proteasome system. Our pre-
vious results showed that PTX/LPC treatment 
induced a weakness of Akt-Mdm2-p53 complex 
by strongly lowering pS166-Mdm2 levels and this 
increased nuclear p53 levels. Overall, our results 
suggested that p-Akt lowering was at the root of 
the apoptotic action exerted by PTX/LPC combi-
nation and provided strong validation for a treat-
ment approach that targets inhibitor of apoptosis 
proteins and survival signals.
Constitutive Akt activation is related to a more 
aggressive phenotype in various human cancers31 
and it contributes to cancer progression via pleio-
tropic effects, including suppression of apoptosis 
and modulation of cell-cycle regulation. Akt plays 
a key role in mitogenic pathway controlled by 
PI3K. Under normal PI3K/Akt signaling, PI3K is 
recruited to the cell surface through binding to a 
receptor tyrosine kinase (RTK) and phosphorylates PIP2 to gen-
erate PIP3, a critical second messenger which leads to the activa-
tion of Akt.32 Akt is crucial in downstream signaling of multiple 
RTK of pathogenic importance in cancer development,33 in par-
ticular in the mitogenic signal activated by IGF-1R/IRS-1 com-
bination.34,35 We have previously shown that in Y79 cells IGF-1/
IGF-1R mediates an autocrine growth mechanism which induces 
the tyrosine phosphorylation of IRS-1 and we suggested that this 
autocrine loop can be the leading cause of the uncontrolled pro-
liferation of human retinoblastoma Y79 cells.36
Most highly malignant human cancers have dysregulated 
PI3K/Akt signaling cascades which lead to abnormally increased 
cell proliferation.33 Here, we show for the first time that in human 
retinoblastoma Y79 cells combination of OKA with PN at sub-
toxic doses, induces a potent synergistic apoptotic effect. Our 
results demonstrate that, likely to PTX/LPC combination, OKA/
PN combination induces apoptosis by lowering p-Akt levels and 
favoring p53 stabilization through a potent decrease in the level 
of pS166-Mdm2. However, here we also show the key involve-
ment of PTEN which potently increases after OKA/PN treat-
ment. Unlike most of the protein tyrosine phosphatases, PTEN 
preferentially dephosphorylates phosphoinositide substrates by 
converting PIP3 to PIP2.37 In such a manner, PTEN functions as 
a tumor suppressor by antagonizing PI3K/Akt signaling pathway. 
Figure 4. OKa/PN induces ROs generation and depletion of intracellular Gsh. (A) Graph 
shows ROs generation measured by flow cytometry as described in materials and meth-
ods. Data are the mean ± sD of three independent experiments, each performed in trip-
licate. Data were considered significant at *P < 0.05 and highly significant at #P < 0.01 as 
compared with the control group. (B) The figure shows the shift of fluorescence intensity, 
observed at 6 h after OKa/PN treatment and indicating a potent increase in ROs level. (C) 
The graph shows the induced depletion of intracellular Gsh measured by the colorimetric 
assay reported in materials and methods. Data are the mean ± sD of three independent 
experiments, each performed in triplicate. Data were considered significant at *P < 0.05 
and highly significant at #P < 0.01 as compared with the control group. (D) The figure 
shows the effect of pre-treatment with BsO on sensitivity to OKa/PN. Data are the mean ± 
sD of three independent experiments, each performed in triplicate. Data were considered 
significant at *P < 0.05 as compared with the control group.
However, PTEN may have additional phosphatase-independent 
activities and can also play other critical roles in multiple aspects 
of cancer development.38 PTEN is the second most frequently 
mutated gene in human cancer after p53,39 and PTEN loss is 
observed in many malignant tumors where it is often a marker 
for advanced neoplastic disease.40,41 Upon PTEN loss, exces-
sive accumulation of PIP3 at the plasma membrane recruits and 
activates Akt, potently driving cell proliferation and apoptosis 
resistance.42 Conversely, treatment of cancer cells with drugs 
which induce PTEN upregulation determines potent apoptotic 
effects.43 Apoptosis is an active process which can be triggered 
in tumor cells by a number of different stimuli, among which 
considerable evidence implicates oxidative stress as a mediator.44 
To this regard, it has been suggested that programmed cell death 
has evolved as a mechanism to eliminate cells which become 
producers of large amount of ROS.45 The biological activity of 
PN is thought to be mediated through its α-methylene-γ-lactone 
moiety, which can react with nucleophiles, especially with cys-
teine thiol groups. By its chemical properties PN modifies cel-
lular redox state and induces cell death.31 Even OKA is a strong 
inducer of oxidative stress, in particular on neuronal cells.46 We 
have already shown that in Y79 cells apoptosis can be mediated 
by oxidative stress.16 Here we demonstrate that apoptosis induced 
by OKA/PN treatment is accompanied by a potent increase in 
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min of OKA/PN treatment, significantly before p53 increase. 
This suggests that p53 activation could be under the action of 
PTEN as also evidenced by knockdown of PTEN where pAkt/
pS166-Mdm2 increased over basal levels, while p53 significantly 
lowered. In addition, in PTEN-silenced cells OKA/PN treat-
ment was unable to lower both p-Akt and pS166-Mdm2 below 
basal levels and to increase p53 over basal level. Regarding to 
cell viability, oxidative stress and GSH content, we observed that, 
respect to control cells, in PTEN-silenced cells OKA/PN treat-
ment induced a lesser-reduction of cell viability, a lesser produc-
tion of ROS and a lower decrease in GSH content.
To our knowledge our study report for the first time both 
a synergistic apoptotic action between OKA and PN and the 
involvement of PTEN as key player in the apoptotic mechanism 
in human retinoblastoma Y79 cells. The results provide strong 
suggestion for a combining treatment approach that targets the 
PTEN/Akt/Mdm2/p53 pathway.
Materials and Methods
Cell culture. Human retinoblastoma Y79 cells—purchased from 
Interlab Cell Line Collection—were cultured in suspension in 
T-75 flask in RPMI 1640, supplemented with 15% (v/v) heat-
inactivated fetal bovine serum, 2 mM l-glutamine and antibi-
otics (50 U/ml penicillin–50 μg/ml streptomycin) (Euroclone) 
in a humidified atmosphere of 5% CO
2
 in air at 37 °C. Media 
were replaced every 2–3 d. For monolayer cultures Y79 cells were 
seeded into 96-well plates (5 × 104 cells/well) or 6-well plates 
(1.5 × 106 cells/well), precoated with 5 μg/cm2 poly-d-lysine 
(Sigma-Aldrich). Cells were treated with OKA and/or PN for the 
time indicated in the results and, then were removed by pipetting 
up and down and pelleted at 1000× g. OKA and PN were sup-
plied by Sigma-Aldrich, prepared as a stock solution (621 μM 
and 40 mM respectively) in dimethylsulfoxide, protected from 
light, preserved at −20 °C and diluted to working concentra-
tion with culture medium. Final concentrations of DMSO never 
exceeded 0.04%.
Cell viability. For these studies the cells were seeded into 
96-well plates as above reported. Twenty-four hours after seeding, 
cells were treated with drugs for the time indicated in the Results. 
Cell viability was determined by the MTT colorimetric assay.47 
MTT is reduced to purple formazan in the mitochondria of liv-
ing cells. The absorbance of the formazan was measured at 570 
nm, with 630 nm as a reference wavelength using an automatic 
ELISA plate reader (OPSYS MR, Dynex Technologies). After 
drugs treatment, cell survival was estimated as a percentage of the 
value of the vehicle-treated control. In some experiments trypan 
blue was used to count viable cells with comparable results.
Apoptotic morphology. Apoptotic morphology was detected 
by either Hoechst 33258 fluorescent staining (Sigma-Aldrich) or 
by acridine orange and ethidium bromide (A/E) (Sigma-Aldrich), 
the fluorescent DNA-binding dyes. For these studies, after seed-
ing into 96-well plates, Y79 cells were treated with OKA and PN 
individually and in combination for the indicated times at 37 °C. 
Thereafter, the incubation medium was removed and cells were 
washed with phosphate-buffered saline (PBS). For Hoechst 33258 
ROS level with a simultaneous decreases in that of GSH; the 
results also show that reducing cellular GSH levels by glutathione 
depleting agent BSO, significantly anticipates the time of cyto-
toxic effect exerted by OKA/PN. Indeed, in cells pretreated with 
BSO, OKA/PN treatment markedly induced loss in cell viability 
after 3 h of treatment, an event that in non-pretreated cells was 
determined after 6 h of treatment. Overall, the results suggest 
that Y79 cells could be prone to oxidative stress.
In this study we show a molecular scenario in which PTEN 
plays a key role in OKA/PN-induced effects. Indeed, PTEN 
induction and p-Akt lowering were already evident after 30 
Figure 5. effects of OKa/PN treatment on PTeN/akt/Mdm2/p53 path-
way. (A and B) describe western blotting analyses after 6 h of drugs 
treatment. actin was used as the loading control. Images are represen-
tative of at least four independent experiments. (C) The effect of 6 h of 
drugs treatment on p53 localization by fluorescence microscopy. Cells 
were triple stained with (1) hoechst 33258 dye (blue), to localize the 
nucleus; (2) rhodamine-conjugated secondary antibody (red) to local-
ize cytosolic actin; (3) FITC-conjugated secondary antibody (green) to 
localize cytosolic/nuclear p53. The right panels show the merge of the 
three dyes. (Original magnification 400×.) Images are representative of 
at least four independent experiments.
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DNA staining, cell suspensions were centrifuged, washed 3 times 
with PBS and resuspended at 1 × 106 cells/ml in PBS. Cells were 
mixed with cold absolute ethanol and stored for 1 h at 4 °C. After 
centrifugation, cells were rinsed 3 times in PBS and the pellet 
was suspended in 1 ml of propidium iodide (PI) staining solu-
tion (3.8 mM sodium citrate, 25 μg/ml PI, 10 μg/ml RNase A; 
Sigma-Aldrich) and kept in the dark at 4°C for 3 h prior to flow 
cytometry analysis. The proportion of cells giving fluorescence 
in the sub-G
0
/G
1
 peak of cell cycle was taken as a measure of 
apoptosis.
For Annexin V labeling, cell suspensions were centrifuged, 
washed 3 times with PBS and resuspended in 1X Annexin V 
binding buffer (BD Biosciences PharMingen) at a concentra-
tion of 1 × 106 cells/ml. One hundred microliters of cell sus-
pension was then incubated with 5 μl of Annexin V-FITC (BD 
Biosciences PharMingen) and 5 μl of PI for 15 min at a room 
temperature in the dark. Double labeled with annexin V and PI 
allows a distinction of early apoptotic (annexin V+/PI−) and late 
apoptotic/necrotic (annexin V+/PI+) cells.
Flow cytometry analyses were performed by a COULTER 
EPICS XL flow cytometer (Beckman Coulter Srl) equipped with 
a single Argon ion laser (emission wavelength of 488 nm) and 
Expo 32 software. The green fluorescence was measured in the 
FL1 channel using a 515 nm BP filter and the red fluorescence 
was measured in the FL3 channel using a 620 nm BP filter. At 
least 1 × 104 cells per sample were analyzed and data were stored 
in list mode files.
Evaluation of ROS generation. Intracellular ROS produc-
tion was determined by detecting the fluorescent intensity of the 
fluoroprobe 5-(and6)-carboxy-2', 7'-dichlorodihydrofluorescein 
staining, the cells were fixed with methanol/acid acetic (3:1) for 
10 min at room temperature and after washing with PBS, the 
cells were incubated with Hoechst 33258 (5 μg/ml) for 10 min at 
room temperature. For A/E staining, the cells were treated with a 
solution composed of A/E (100 μg/ml PBS of each dye). Samples 
were examined on a Leica DM IRB inverted microscope (Leica 
Microsystems Srl) equipped with fluorescence optics and suitable 
filters for DAPI, FITC and rhodamine detection; images were 
photographed and captured by a computer-imaging system (Leica 
DC300F camera and Adobe Photoshop for image analysis).
Immunofluorescence analysis to evaluate cytoplasmic–
nuclear shuttling of p53. Y79 cells were grown in 6-well plates, 
after treatments the cells were washed with PBS, fixed with 
3.7% formaldehyde and permeabilized with 0.1% Triton X-100 
(Sigma) in PBS. All antibodies were diluted in PBS + 1% BSA 
+ 0.05% NaN3 (Sigma-Aldrich). The cells were incubated over-
night at 4°C with a mixture of rabbit monoclonal antibody 
against actin (diluted 1:2000; Sigma) and mouse monoclonal 
antibody against p53 (diluited 1:500; Santa Cruz Biotechnology 
Inc.). The cells were then washed in PBS, incubated with Cy3-
conjugated donkey anti-rabbit IgG (H+L) secondary antibody 
(diluted 1:100; Jackson ImmunoResearch Laboratories) for 1 h 
at room temperature and then with Cy2-conjugated donkey anti-
mouse IgG (H+L) secondary antibody (diluted 1:100; Jackson 
ImmunoResearch Laboratories) for another hour. Nuclei were 
visualized after staining with Hoechst 33258 (5 μg/ml) at room 
temperature for 10 min. Samples were examined on a Leica DM 
IRB inverted microscope, as above reported.
Flow cytometry analysis. Apoptosis was also studied by flow 
cytometry of either DNA content or Annexin V labeling. For 
Figure 6. effects of silencing PTeN gene on the molecular players which control apoptosis. Western blot analysis of (A) knockdown efficiency of PTeN 
protein, and (B) of 6 h of drugs treatment on both untransfected cells and PTeN-siRNa or scrambled siRNa (scr-siRNa) transfected cells. actin was used 
as the loading control. Images are representative of at least four independent experiments. (C) effects of 6 and 12 h of OKa/PN treatment on both Gsh 
content (left) and cell viability (right) under the conditions described in (B). Data are the mean ± sD of three independent experiments, each per-
formed in triplicate. Data were considered significant at *P < 0.05 and highly significant at #P < 0.01 as compared with scr-siRNa transfected cells.
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Western blot analysis. For these studies, after treatment, cells 
were washed in PBS and lysed for 30 min at 4°C in ice-cold lysis 
buffer (1% NP40, 0.1% SDS, and 0.5% sodium deoxycolate in 
PBS) containing protease inhibitor cocktail. Then, cells were son-
icated three times for 10 s. Equal amounts of protein samples (40 
μg/lane) were subjected to SDS-PAGE and then transferred to a 
nitrocellulose membrane (Bio-Rad Laboratories Srl) for detection 
with specific antibodies anti-phospho Mdm2 (Ser166), anti-phos-
pho p53 (Ser46) (diluted 1:500; Cell Signaling), anti-acetyl p53 
(Lys 373–382) (diluited 1:500; Millipore Corporation). Unless 
otherwise specified all antibodies (diluted 1:1000) were purchased 
from Santa Cruz Biotechnology. The secondary horseradish 
peroxidase-labeled goat anti-mouse and goat anti-rabbit anti-
bodies were from Amersham Life Science Inc. Immunoreactive 
signals were detected using enhanced chemiluminescence (ECL) 
reagents (Bio-Rad). The correct protein loading was confirmed 
by stripping the immunoblot and reprobing with primary anti-
body for actin (diluted 1:500; Sigma). Protein concentration was 
assayed using Bradford method (Bio-Rad Laboratories).
Statistical analysis. Data, represented as mean ± S.D., were 
analyzed using the 2-tailed Student t test. Differences were con-
sidered significant when P < 0.05.
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diacetate (H2-DCFDA) (Molecular Probes). Y79 cells grown 
in 6-well plates at the density of 1.0 × 106/well were treated 
with drugs. Thereafter, the cells were detached and collected by 
centrifugation into a 15 ml Falcon tube. The dissociated cells 
were resuspended in 0.5 ml of pre-warmed PBS containing 
H2-DCFDA (50 μM) and allowed to recover for 30 min in the 
darkness.
Flow cytometry analysis was performed by a COULTER 
EPICS XL flow cytometer, as above reported. The amount of 
ROS production was considered to be directly proportional to 
the green fluorescence intensity.
Measurement of intracellular glutathione (GSH). The intra-
cellular GSH concentration was measured using a commercial 
assay, provided by OXIS Research. After treatment, the cells (5 
× 105/well) were collected, and centrifuged at 1000× g for 8 min. 
The pellets were washed in PBS and resuspended in 50 μl meta-
phosphoric acid (5 g/100 ml distilled water). GSH content was 
measured as described by manufacturer’s instructions.
Then the samples were read at 400 nm. The absorbance was 
determined by an automatic ELISA plate reader. The final con-
tent of intracellular GSH was expressed as nanomoles of GSH 
per 106 cells.
Cell transfection of siRNA PTEN. Y79 cells were seeded 
(5 × 105 cells/well) in 6-well plates and cultured in RPMI 
1640 medium, supplemented with 15% FBS, for 24 h to reach 
approximately 60–80% confluence before transfection. Specific 
siRNAs directed against PTEN, obtained by Santa Cruz 
Biotechnology as a pool of double-stranded RNA oligonucle-
otides, were transfected for 5 h into the cells at a final concen-
tration of 50 nM, in the presence of 5 μl Lipofectamine 2000 
(Invitrogen) in a final volume of 1 ml serum-antibiotic free 
RPMI 1640. At the end the reaction was stopped replacing the 
culture medium with RPMI 1640 +15% FBS. Cells were exam-
ined for PTEN downregulation and other properties 24–72 h 
after transfection. siRNA, consisting in a scramble sequence, 
was used as a negative control.
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